Skip to main content
Erschienen in: Breast Cancer Research 5/2005

01.10.2005 | Editorial

Overdiagnosis and breast cancer screening

verfasst von: Nick E Day

Erschienen in: Breast Cancer Research | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Excerpt

Screening for breast cancer is now routinely performed in most countries where the disease is common. The benefits of screening have been established and are generally accepted. However, screening does have the potential for harm, the most important aspects of which are overdiagnosis and overtreatment. Breast Cancer Research has invited a series of papers to address the component dimensions of the field, and in particular to estimate the extent to which it occurs. The first article in the series, in which Sue Moss reviews overdiagnosis in randomised controlled trials of breast cancer screening, is published in this issue [1]. …
Literatur
1.
Zurück zum Zitat Moss S: Overdiagnosis and overtreatment of breast cancer: Overdiagnosis in randomised controlled trials of breast cancer screening. Breast Cancer Res. 2005, 7: 230-234. 10.1186/bcr1314.CrossRefPubMedPubMedCentral Moss S: Overdiagnosis and overtreatment of breast cancer: Overdiagnosis in randomised controlled trials of breast cancer screening. Breast Cancer Res. 2005, 7: 230-234. 10.1186/bcr1314.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat International Agency for Research on Cancer: IARC Handbooks of Cancer Prevention. Cervix Cancer Screening. 2005, Lyon: IARC Press International Agency for Research on Cancer: IARC Handbooks of Cancer Prevention. Cervix Cancer Screening. 2005, Lyon: IARC Press
3.
Zurück zum Zitat Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RAM, Schroder FH, de Koning HJ: Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003, 95: 868-877.CrossRefPubMed Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RAM, Schroder FH, de Koning HJ: Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003, 95: 868-877.CrossRefPubMed
4.
Zurück zum Zitat Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ: Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002, 94: 981-90.CrossRefPubMed Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ: Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002, 94: 981-90.CrossRefPubMed
5.
Zurück zum Zitat International Agency for Research on Cancer: IARC Handbooks of Cancer Prevention. Breast Cancer Screening. 2002, Lyon: IARC Press International Agency for Research on Cancer: IARC Handbooks of Cancer Prevention. Breast Cancer Screening. 2002, Lyon: IARC Press
Metadaten
Titel
Overdiagnosis and breast cancer screening
verfasst von
Nick E Day
Publikationsdatum
01.10.2005
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 5/2005
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1321

Weitere Artikel der Ausgabe 5/2005

Breast Cancer Research 5/2005 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.